Summary Improvements to the original procedure of using a panel of monoclonal antibodies and magnetic microspheres for the depletion of tumour cells from bone marrow are described. These include a completely disposable system for the magnetic depletion of tumour cells coated with magnetic microspheres. Properties of a new series of microspheres are compared with the old M330 beads in their ability to deplete neuroblasts from both model systems and 50 bone marrows harvested from Stage IV neuroblastoma patients. Using human neuroblastoma cell lines labelled with the DNA intercalating, Hoechst dye 33342 a 5% tumour contamination can routinely be removed from 5x 106-5 x 107 nucleated cells. Analysis of the 50 purged marrows revealed that 10 were visibly contaminated with tumour (by conventional cytology and immunological procedures). In all but one case, tumour cells were removed. In this instance the tumour:bead ratio fell to 1:4 indicating the importance of maintaining a sufficient number of beads in the system. Red cell contamination of marrow was also kept extremely low so preventing possible physical blockade of bead:tumour cell interaction. Marrow engraftment was rapid in this group, apart from patients who had been exposed to high doses of alkylating agents prior to autografting.
A variety of techniques have been developed to deplete tumour cells from bone marrow harvested for autologous transplantation . Of these, four have been used either experimentally or clinically for the removal of neuroblasts from marrow taken from children with Evans stage IV neuroblastoma (Evans et al., 1971) . Reisner (1983) has shown that, in model systems, he could obtain a limited depletion of neuroblasts from bone marrow using soybean agglutinin. Saarinen et al. (1985) have described, in model systems, the use of a murine monoclonal antibody of the IgG3 isotype (recognising the ganglioside GD2) and human complement for killing tumour cells in bone marrow. However the use of a single antibody and complement for purging marrow is unlikely to lead to maximal tumour kill as Gee et al. (1986) have demonstrated that this leads to the selection of cells of low antigen density, resistant to complement mediated cytolysis.
The derivative of cyclophosphamide, Asta Z, has been used to 'chemically purge' neuroblasts from bone marrow harvested for autologous transplantation (Douay, 1985) . Whilst this is effective in model systems using relatively rapidly dividing cell lines, it may not efficiently kill fresh neuroblastoma cells, Correspondence: J.T. Kemshead . Received 14 May, 1986. many of which may be in the GI/GO phase of the cell cycle (Danon et al., 1980) . Alternatives for the chemical purging of neuroblasts from bone marrow are dopamine and ascorbic acid (Reynolds et al., 1982) and the analogue of epinephrine/norepinephrine, meta-iodobenzylguanidine radiolabelled with 131-I (Buck et al., 1985) . In addition the photoactivation of merocyanine 540 which is reported to be selectively taken up into the membranes of certain leukaemic and neuroectodermal cell lines is another approach to investigating tumour cell kill in bone marrow (Sieber et al., 1986) .
The physical removal of neuroblastoma cells from bone marrow using an elutriation centrifuge has been described by Figdor et al., (1985) . This was reported capable of depleting only -90% of tumour cells from marrow. An alternative physical procedure is to use a panel of monoclonal antibodies and magnetic microspheres (Treleaven et al., 1984) . This is effective for the removal of neuroblastoma cell lines and fresh neuroblasts from bone marrow with an efficiency of at least three logarithmic units of tumour depletion (Treleaven et al., 1984 ). An indirect approach to targetting microspheres to tumour cells has been adopted. Initially monoclonal antibodies are added to contaminated bone marrow and these bind selectively to the tumour cells. Microspheres coated with anti-mouse Ig are then added to the system which bind to the antibody-coated cells. (Treleaven et al., 1984) .
Over the last two years the original method for the depletion of neuroblastoma cells from bone marrow has been considerably modified. Here we detail these modifications and report on the first 50 marrows from neuroblastoma patients treated by this technique. This represents -30% of the total 'magnetic' marrow purges that have been undertaken for neuroblastoma and other malignancies in the collaborative groups investigating this technique.
Materials and methods
Preparation of microspheres Both the M330 and 450 series of microspheres are magnetic polymer beads of uniform size prepared by the method of Ugelstad et al. (1984) . To obtain a monodispersed preparation of microspheres, suspensions of M330 microspheres were sonicated as described previously (Treleaven et al., 1984 Figure 1 . The treated marrow was attached to the first chamber using a Travenol 2243 line. The marrow was 'pulled' through the system at a constant rate of 2.5 ml min-I using a peristaltic pump. This was placed after the magnetic separation chambers to avoid disruption of the tumour cell/bead complexes. The separation chambers and marrow were kept at 4°C during the purging procedure. A Travenol 2244 connector was used to link the last chamber to the pump and a similar connector used to attach a Travenol 600 ml transfer pack to the apparatus to collect marrow purged of tumour. The chambers were flushed free of haemopoietic progenitors using saline containing 10% PPF v/v to maximise cell yields.
Tumour cell depletion and assessment of haemopoietic progenitor recovery In the model system studied neuroblastoma cells were initially incubated with the DNA binding dye Hoechst 33342 according to the method of Reynolds et al. (1985) . These were titrated into either peripheral blood or bone marrow at different percentages (1-10%). Removal of tumour cells from the system was determined by estimating the number of fluorescent cells remaining in the cell mixture under UV fluorescent microscopy. Before analysis samples were mixed with trypan blue to exclude the possibility of dye being taken up by dead cells.
Tumour cell removal from fresh bone marrow was determined by indirect immunofluorescence using monoclonal antibodies and fluorescein conjugated sheep anti-mouse Ig. Several antibodies used in this study [PI153/3 (Kennett & Gilbert, 1979) , A2B5 (Eisenbarth et al., 1979) , UJ167.11, UJ223.8] were not employed in the magnetic depletion procedure. Assays for haemopoietic progenitor cells, (CFUc, BFUe and CFUgem) were undertaken according to the method of Fausner and Messner (1979) . Samples were also checked for bacterial and fungal contamination in the Bacteriology Dept., Hospital for Sick Children.
Results

Magnetic microspheres
The properties of the new M450 microspheres are listed in Table I . Unlike the M330 series of microspheres the M450 beads become completely monodipersed upon suspension in either water or PBS (no sonication needed). They are resistant to most organic solvents enabling them to be rapidly sterilised. Like the 330 series of beads which they replace, they are uniform, both in size and in the amount of magnetite they contain ( Figure 2A ). The major functional differences in the M450 microspheres over the old beads are a 5-fold reduction in the number of beads/mg, and a 30-fold reduction in their surface area (Table I ). This reduces consider- bead: tumour ratio of -30:1 increased quantities of beads need to be used in the purging procedure (see below). An overall saving of 70-80% of anti-mouse Ig can however be made using the M450 rather than the M330 microspheres.
Preparation of buffy coat fractions from bone marrow Although it was aimed to harvest 3 x 108 nucleated cells kg-1 body wt from each patient, considerable variations in cell counts were obtained (1.1-8.0 x 108 kg '; n = 50). Volumes of harvested marrow ranged from 150-850 ml. For volumes <400 ml the Erytrenn cell separator was used in preference to the IBM apparatus for buffy coat preparation. The relatively large capacity of the IBM 2991 bag (650 ml) makes this difficult to use with small volumes of bone marrow without adding a dense inert fluid, e.g. glycerol, to reduce the internal capacity of the bag. Red cell contamination
Haemopoietic cell recoveries Figure 3 shows that purging marrow of neuroblastoma cells with either the M330 series of microspheres (n = 14) or the M450 beads (n = 36) results in similar losses of cells. In both instances a mean of 65-70% of nucleated cells were recovered, although considerable variation in the percentage recoveries were noted (M330 beads, 42-111%; M450 series, 38-87%). Recovery of cells was independent of the original cell count and although several marrows were contaminated with tumour cells these could not account for the overall losses observed.
Studies on colony assays pre and post separation with antibodies and either series of microspheres showed a small but non-selective loss of haemopoietic progenitors per 105 mononuclear cells (Table II) (Table III) . In all of these cases except one, tumour cells were removed from the marrow after incubation with monoclonal antibodies and magnetic microspheres. In this instance the ratio of beads to tumour cells was 4:1. This occurred as the marrow was not tested for the degree of tumour cell involvement prior to the purging procedure.
Whilst efficient tumour purging occurred with M450 beads at bead:tumour ratios of -12-17:1, . Two patients relapsed between the marrow harvest and the ablative therapy and treatment was not continued. Ten marrows remain frozen to be used at a later date in the childrens' management. Data are available on 21 individuals of which 4 succumbed to infection prior to regraftment (within 30 days of giving the graft). This was not due to contamination of the marrow during the purging procedure as assessed by bacterial/fungal screening. Thirteen of 17 patients were given a high dose ablative protocol in first remission. Of these 6 marrows were purged using the M330 beads. The mean time (T) for recovery to 500 neutrophils was 21.5 days (range 17-24) and 50,000 platelets 30.3 (range 19-43) days. The remaining 7 were purged using the M450 microspheres and similar recovery times were noted T-500 neutrophils, 22 days (range 14-36) and T 50,000 platelets, 33 days (range 19-38). The remaining 4 patients who were grafted in second remission, had considerably longer recovery times (mean T500 neutrophils 46 days; mean T50,000 platelets 81.5 days). All of these had been previously exposed to relatively high doses of alkylating agents, which presumably caused damage to either marrow progenitors or stromal elements associated with haemopoietic recovery.
It is not possible to acquire accurate data on the survival of this group of patients as they have been treated in different centres, using different induction and ablative protocols (see Discussion).
Discussion
The use of magnetic microspheres and panels of monoclonal antibodies for the depletion of tumour cells from bone marrow is an extremely fast, efficient and cost effective procedure (Treleaven et al., 1984) . The modifications described here represent considerable improvements over the original method, economising on reagents, the time involved in the procedure, and allowing a completely disposable system to be used for the magnetic separation chambers. The indirect approach to depleting tumour cells from bone marrow allows for the saturation of antigen binding sites on malignant cells, and attempts to overcome the problem of antigen heterogeneity known to occur in tumour cells (Kemshead et al., 1983) .
Adaptations of the indirect procedure described above are currently being explored by others in experimental systems (Sawada et al., 1986) .
The indirect system of depleting tumour cells from bone marrow has been used to purge marrow harvested from 14 children with acute lymphoblastic leukaemia. Obviously in these cases a different panel of antibodies has been applied to the marrow. Whilst the reagents show very low cross reactivity with cells in normal bone marrow (<1%), the levels of nucleated cell and committed haemopoietic cell progenitors recovered are considerably and consistently lower than for the neuroblastoma patients (Kemshead, in preparation) . These patients have engrafted well on the whole, but the observation suggests that the use of different antibodies with the magnetic microspheres may considerably alter cell recoveries obtained and by implication the efficiency of tumour cell removal.
No direct comparison of other purging procedures has been undertaken for neuroblastoma on marrows used clinically, since in the laboratory other procedures have produced results that are inferior to the magnetic separation technique. However, Favrot et al. (1985) have compared the efficiency of antibody and complement and magnetic tumour cell depletion using marrow contaminated with Burkitt's lymphoma cell lines. Using a modified system to that described above employing a mononuclear cell fraction rather than buffy coat and double depletion procedure, Favrot Although it is too early to be confident of survival, several children given high dose radio/chemotherapy when in complete remission remain well over two years post transplantation. The role of purging in this group is difficult to establish. The known patchy involvement of neuroblastoma in bone marrow makes accurate detection of tumour extremely difficult. In two cases of the 50 described here, marrow aspirates appeared free of tumour cells one month prior to the harvest for transplantation and yet a heavy infiltrate was found when the autograft was prepared. These observations provide the most compelling reasons for purging marrow from Stage IV neuroblastoma patients apparently in complete remission. The current ablative regimens used in Stage IV neuroblastoma carry a considerable risk of toxicity. As well as facilitating the clinical application of this type of therapy, research efforts should continue to improve the purging procedure and reduce overall toxicity. This may be accomplished in the future by the further in vivo use of monoclonal antibodies as agents to target radioisotopes to minimal residual disease. Toxicity of this type of therapy is currently being assessed but it is likely to be considerably less than the problem associated with giving external beam total body irradiation to children.
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